| HOME >> MEDICINE >> TECHNOLOGY |
6. AREAS OF INDICATION II-42
Indications for Anticoagulant Use II-42
Venous/DVT Thrombosis Indications II-42
Desired Anticoagulant Qualities for DVT Indications II-42
Venous Thromboembolism II-42
Deep Vein Thrombosis II-42
Pulmonary Embolism II-44
Orthopedic (Hip or Knee Replacement) Surgery II-45
General Surgery II-46
Cancer II-46
Arterial Thrombosis Indications II-47
Arterial Thrombosis II-47
Acute Coronary Syndromes II-47
Atrial Fibrillation II-48
Unstable Angina II-49
List of Approved Anticoagulants for Unstable Angina II-50
Myocardial Infraction II-50
Non ST-Segment Elevation MI II-50
List of Approved Anticoagulants for Non-ST Segment
Elevation Myocardial Infarction II-51
Percutaneous Transluminal Coronary Angioplasty (PTCA) II-51
List of Approved Anticoagulants for Angioplasty Procedures II-52
Heparin Induced Thrombocytopenia (HIT) Indications II-52
HIT Type I II-52
HIT Type II II-52
Heparin Induced Thrombocytopenia with Thrombosis (HITTS) II-54
Other Indications II-54
Hemodialysis II-54
7. DRUG DEVELOPMENT PIPELINE II-55
Select Anticoagulants in Clinical Development II-55
Anticoagulant Therapies in Development Stage II-56
Idraparinux - Sanofi II-56
0673 - Sanofi II-56
MER-102 II-56
Semuloparin Sodium (AVE 5026) II-56
8. PRODUCT INTRODUCTIONS/APPROVALS II-57
Mitsubishi Pharma Introduces Argatroban in the UK II-57
Bayer Obtains Canadian Approval for Xarelto in the Treatment
of Deep Vein Thrombosis II-57
Pradaxa Gains Regulatory Approval in Japan for Prevention of
Stroke II-57
Pfizer and Bristol-Myers Launch ELIQUIS Black Triangle Drug II-57
ELIQUIS® Receives Approval in EU in Prevention of VTE II-58
Xarelto Obt
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |